Amylyx Pharmaceuticals, Inc. AMLX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s pre-tax income?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported pre-tax income of -$32.95M in Q4 2025.
- How has Amylyx Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s pre-tax income increased by 13.7% year-over-year, from -$38.18M to -$32.95M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s pre-tax income?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s pre-tax income has grown at a 13.3% compound annual growth rate (CAGR), from -$87.93M to -$144.69M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.